<a href="https://www.fiercebiotech.com/biotech/cancer-biotech-parabilis-ups-ipo-plans-potentially-record-setting-637m" hreflang="en">Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M</a>
Parabilis Medicines has increased its IPO plans to potentially raise up to $637 million, aiming to surpass the record set by Kailera Therapeutics. The funds will primarily support the development of its lead drug, zolucatetide, for treating desmoid tumors and other rare cancers.
Parabilis Medicines is making headlines by potentially setting a new record for biotech IPOs with a target of up to $637 million, indicating strong market confidence in their novel helicon peptides platform. This marks a significant investment signal, particularly for those tracking advancements in targeting previously undruggable pathways like the Wnt/β-catenin signaling, crucial in many cancers. Keep an eye on Parabilis' progress, as the IPO proceeds are earmarked for advancing their lead candidate, zolucatetide, which has already received FDA fast-track designation.